A5053429397- Parathyroid Disorders and Treatments
- Atrial Fibrillation Management and Outcomes
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Coronary Interventions and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac tumors and thrombi
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac Arrhythmias and Treatments
- Brain Metastases and Treatment
- Cardiovascular Function and Risk Factors
- COVID-19 Clinical Research Studies
- Cardiovascular Effects of Exercise
- Long-Term Effects of COVID-19
- Cancer Treatment and Pharmacology
University of Chicago Medical Center
2024
University of Pennsylvania
2023-2024
Université de Montréal
2022-2023
Hôpital Maisonneuve-Rosemont
2023
Montreal Heart Institute
2022
Centre Hospitalier de l’Université de Montréal
2020
Abstract Aims Although impaired left ventricular (LV) global longitudinal strain (GLS) with apical sparing is a feature of cardiac amyloidosis (CA), its diagnostic accuracy has varied across studies. We aimed to determine the ability ratio (ASR) and most common echocardiographic parameters differentiate patients confirmed CA from those clinical and/or suspicion but this diagnosis ruled out. Methods results identified 544 200 controls (CTRLs) as defined above (CTRL patients). Measurements...
The objective is to assess the comparative effectiveness and safety of dual-antiplatelet therapy (DAPT) vs triple (TT) with DAPT + oral anticoagulant (OAC) in patients anterior ST-segment elevation myocardial infarction (STEMI) new-onset anterior/apical wall-motion abnormalities (WMAs) treated primary percutaneous coronary intervention (PCI).
In patients with anterior ST-elevation myocardial infarction (STEMI) and new-onset antero-apical wall motion abnormalities (WMAs), whether the rate of prophylaxis against left ventricular thrombus outcomes differ between men women is unknown. A multicentre retrospective cohort study STEMI WMAs treated primary percutaneous coronary intervention was conducted. Patients an established indication oral anticoagulation (OAC) were excluded. The rates triple therapy (double antiplatelet + OAC) at...